linjc16/ctgov huggingface dataset:
Observing the Morphology of Schlemm's Canal and Crystalline Lens in Different Age

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to quantify and observe the morphology of trabecular meshwork (TM), Schlemm's canal (SC), ciliary body and crystalline lens before and after cycloplegia in patients with different ages using swept-source optical coherence tomography.

Official Title
-----------------
Morphology of Schlemm's Canal and Crystalline Lens in Different Age: a Swept-source Optical Coherence Tomography Study

Conditions
-----------------
Schlemm's Canal Occlusion

Intervention / Treatment
-----------------
* Device: swept-source optical coherence tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy patients who can cooperated with the swept-source OCT measurements Exclusion Criteria: history of ocular disease presence of central nervous system or systemic disease

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy participants<br>Swept-source optical coherence tomography A device testing TM/SC and Lens morphology | Device: swept-source optical coherence tomography<br>* Aswe pt-source OCT (CASIA SS-1000; Tomey Corporation, Nagoya, Japan), which is specifically designed for anterior segment imaging using a 1310 nm wavelength with a scan speed of 30,000 A-scans per second and an axial resolution of <10 μm.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| area of Schlemm's canal and trabecular meshwork | The area of Schlemm's canal and trabecular meshwork was manually measured and the relationship between the parameters and age was analyzed. | up to 6 months |
Efficacy of Two Onabotulinum Toxin Doses

Study Overview
=================
Brief Summary
-----------------
The changes in bladder function after the injection of Onabotulinum toxin into the detrusor in individuals with neurogenic bladder overactivity will be investigated retrospectively. The records of all patients treated with Onabotulinum toxin injections into the detrusor since 2000 will be evaluated. The changes in the urodynamic values after the injection of 300 units of Onabotulinum toxin will be compared with the changes after the injection of 200 units. Furthermore, the differences in urinary continence, duration between injections, side effects and complications between the two groups will be investigated.

Official Title
-----------------
Comparing the Efficacy of Two Doses of Onabotulinum Toxin for the Treatment of Neurogenic Detrusor Overactivity - a Retrospective Cohort Study

Conditions
-----------------
Neurogenic Bladder, Overactive Detrusor

Intervention / Treatment
-----------------
* Drug: Injection of Onabotulinum toxin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neurogenic detrusor overactivity spinal cord injury Onabotulinum toxin injections into the detrusor from 2000-2017 Exclusion Criteria: missing urodynamic values before or after Onabotulinum toxin injections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Onabotulinum 300 units<br> | Drug: Injection of Onabotulinum toxin<br>* multiple injections of Onabotulinum toxin into the detrusor muscle<br>|
| Onabotulinum 200 units<br> | Drug: Injection of Onabotulinum toxin<br>* multiple injections of Onabotulinum toxin into the detrusor muscle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in detrusor pressure post-injection | bladder detrusor pressure during storage phase | within 3 months before injection; within 2 months after injection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| maximum bladder volume |  | within 3 months before injection; within 2 months after injection | 
| bladder compliance | The relationship between a change in bladder volume and the change in detrusor pressure (ΔDV/ΔDP). | within 3 months before injection; within 2 months after injection | 
| reflexive bladder volume |  | within 3 months before injection; within 2 months after injection | 
| complications |  | within 2 months after injection | 
| presence of urinary incontinence |  | within 3 months before injection; within 2 months after injection |
Chairside Time and Accuracy of Indirect Bonding of Orthodontic Attachments Using Double Versus Single Transfer Tray

Study Overview
=================
Brief Summary
-----------------
compare the chairside time and the accuracy of transferring attachments between single and double sheets vacuum tray techniques during indirect bonding of orthodontic attachments using superimposition on computer software

Official Title
-----------------
Chairside Time and Accuracy of Indirect Bonding of Orthodontic Attachments Using Double Versus Single Transfer Tray: A Randomized Controlled Trial

Conditions
-----------------
Orthodontic Appliance Complication

Intervention / Treatment
-----------------
* Device: double transfer trays
* Device: single transfer tray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with maxillary full set of teeth and undergoing fixed orthodontic treatment. Good oral hygiene. Mild to moderate crowding. Exclusion Criteria: Patients with partially erupted teeth in the maxillary arch. Signs of caries, large restorations or abnormalities of crown morphology. The need of banding. Bad oral hygiene measures.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: single transfer tray<br> | Device: single transfer tray<br>* single soft tray<br>|
| Experimental: double transfer trays<br> | Device: double transfer trays<br>* double trays one soft and one hard<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chairside time of brackets bonding | using Stop watch | an average of 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of orthodontic attachments transfer | linear (mm) scale using geomagic software | one day after bonding | 
| Accuracy of orthodontic attachments transfer | angular (degrees) scale using geomagic software | one day after bonding |
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.

Detailed Description
-----------------
A total of 104 subjects with gBRCA1/2 mutated advanced ovarian cancer is planned to be enrolled to observe the efficacy, safety and PK profile of SC10914. The subjects oral administration SC10914 tablets 400mg on an empty stomach, three times a day, for 28 consecutive days as a treatment cycle, until disease progression (PD) or the toxicity was intolerable. PK blood samples are planned to be collected for each enrolled subject on C1D28 visit.

Official Title
-----------------
SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial

Conditions
-----------------
Advanced Ovarian Cancer

Intervention / Treatment
-----------------
* Drug: SC10914


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sign informed consent voluntarily; ≥18 years old; Histologically confirmed ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer( high-grade carcinoma cancer or endometrioid carcinoma); gBRCA1/2 mutation positive; Had recived at least 2 prior lines of chemotherapy; Platinum sensitive patients; The last line of therapy befor enrollment failed； ECOG≤2； 8. Had at least one measurable lesion. Exclusion Criteria: Any previous treatment with PARP inhibitor; Symptomatic brain metastases; Large amount of fluid in the third gap； Subjects with not enough organ functional reserve at baseline, which met at least one of the following criteria： ANC<1.5×10^9/L PLT<100×10^9/L Hb<100g/L TBIL>1.5×ULN ALT, AST>2.5×ULN (without liver metastases) or ALT, AST>5×ULN (with liver metastases) Cr >1.5×ULN

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SC10914 group<br> | Drug: SC10914<br>* 400mg TID, oral admination on fasting condition<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| objective response rate (ORR) | assessed by the independent imaging assessment committee (recist1.1) | up to 100 weeks (estimated) |
MTA and Biodentine in Pulpotomized Primary Molars

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to evaluate and compare, clinically and radiographically,the effects of MTA and Biodentine when used as pulp dressings following pulpotomy in human primary molars.

Official Title
-----------------
Clinical and Radiographic Outcomes of MTA and Biodentine in Pulpotomized Primary Molars. A Randomized Clinical Trial

Conditions
-----------------
Primary Molar Pulpotomy

Intervention / Treatment
-----------------
* Other: Pulpotomy
* Other: Pulpotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: molars showing: symptomless exposure of vital pulp by caries no clinical or radiographic evidence of pulp degeneration (excessive bleeding from the root canal, internal root resorption, inter-radicular and/or furcal bone destruction) the possibility of proper restoration of the teeth no physiological resorption of more than one-third of the root Exclusion Criteria: presence of systemic pathology and any history of allergic reaction to latex, local anaesthetics or to the constituents of the test pulp dressing agents

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pulp dressing agent<br> | Other: Pulpotomy<br>* Comparison of two different pulp dressing agents<br>* Other names: Biodentine;|
| Active Comparator: Pulp dressing<br>MTA | Other: Pulpotomy<br>* Comparison of two different pulp dressing agents<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of molars with clinical success |  | 12 months | 
| Number of molars with radiographic success |  | 6 and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of molars with no evidence of radicular radiolucency |  | 6 and 12 months | 
| Number of molars with no evidence of internal resorption |  | 6 and 12 months | 
| Number of molars with no evidence of external resorption |  | 6 and 12 months | 
| Number of molars with no evidence of furcation radiolucency |  | 6 and 12 months | 
| Number of molars with no symptoms of pain |  | 6 and 12 months | 
| Number of molars without swelling |  | 6 and 12 months | 
| Number of molars without fistulation |  | 6 and 12 months | 
| Number of molars without pathological mobility. |  | 6 and 12 months |
Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.

Study Overview
=================
Brief Summary
-----------------
Retrospective cohort study to evaluate the effect of the association of PPIs with NSAIDs in work leave time.

Official Title
-----------------
Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.

Conditions
-----------------
Sprain of Ankle

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Work leave due to a sprain of ankle Exclusion Criteria: (none)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with sprain of ankle treated with NSAID | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total work leave time |  | Jan 2007 to Dec 2007 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GI complications |  | Jan 2007 to Dec 2007 | 
| Direct medical costs |  | Jan 2007 to Dec 2007 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GI, NSAID, Complications, Treated, Patients
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.

Detailed Description
-----------------
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood) and determining the dose and dose schedule for the next phase of studies with SNS-595.

Official Title
-----------------
Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies

Conditions
-----------------
Neoplasms

Intervention / Treatment
-----------------
* Drug: SNS-595


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must give written informed consent 18 years of age Advanced solid malignant tumors Tumor can be measured and evaluated Blood tests are within standard limits Normal blood coagulation ECOG Performance Status equal to 0 or 1 Exclusion Criteria: Pregnant or breastfeeding. Women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards. Heart attack, stroke/TIA or other blood clotting event (deep vein thrombosis or pulmonary embolus) within 6 months before the screen visit. Requires kidney dialysis (hemodialysis or peritoneal). Known bleeding disorder (ie, hemophilia, von Willebrand Disease, coagulopathy, etc.). Received an investigational agent or prior chemotherapy or immunotherapy within 28 days before first dose of SNS-595 Receiving therapeutic anticoagulation therapy (coumadin, heparin, etc.). Currently receiving corticosteroids (inhaled steroids for breathing diseases are allowed) or seizure medications. Any medical, psychological, or social condition that, in the opinion of the Principal Investigator, would contraindicate the patient's participation in the clinical trial due to safety and or compliance with study procedures.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SNS-595|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Screening Protein Markers in Patients With Rheumatoid Arthritis and Hot-dampness and Blood Stasis Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the protein markers and to applicate those protein markers in syndrome diagnosis of hot-dampness and blood stasis syndrome in patients with RA.

Detailed Description
-----------------
RA is one of the main disabling diseases in nowadays, which is an autoimmune disease with complex networks mechanism involving multiple signaling pathways and existing cross path. The investigators consider that the heat-dampness and blood stasis syndrome is the main syndrome and major pathogenesis for active RA, which on the base of the theory of traditional Chinese medicine and a large quantity of clinical practice, and also examined by mechanism experiments. But the material basis of this syndrome is remained unclear, lack of high specific objective basis to ensure the syndrome differentiation consistency accurately in clinical practice. Proteomic techniques study cells or the body by all the protein expression and function, thus has the potential efficient for decoding syndrome biological basis. Proteomic techniques are the most effective way to reveal the essence of TCM syndrome. The investigators will use proteomic technology to explore the protein markers and to applicate those protein markers in syndrome diagnosis of hot-dampness and blood stasis syndrome in patients with RA. With strong clinical applicability, this will reveal the scientific connotation of this syndrome, preliminarily guide the syndrome differentiation.

Official Title
-----------------
Screening Sensitive Protein Markers and Exploring Application in Syndrome Diagnosis of Hot-dampness and Blood Stasis Syndrome in Patients With Rheumatoid Arthritis

Conditions
-----------------
Arthritis, Rheumatoid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects are made or confirmed diagnosis according to the American College of Rheumatology criterion and heat-dampness and blood stasis syndrome according to Traditional Chinese Medicine. Exclusion Criteria: Subjects have other serious diseases, such as liver and kidney disease, cerebral-cardio vascular diseases. Subjects, who belong to non-heat-dampness and blood stasis syndrome, have double syndrome of heat or dampness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum and saliva protein markers |  | six hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rheumatoid Arthritis, Heat-dampness and blood stasis syndrome, Protein markers
Physical Disability in Patients Treated With Betaferon

Study Overview
=================
Brief Summary
-----------------
To gather Observation data about physical disability progression, safety and adherence during the use of Betaferon in daily practice. Patients with any type of Multiple Sclerosis (MS) (MRRS) (PSMS), under treatment with Betaferon.Open Multicentric Observational study.24 months.Evaluation of physical disability in patients treated with Betaferon, using Kurtzke's expanded disability scale (EDSS) in biannual periods

Official Title
-----------------
Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Drug: Interferon-1beta (Betaseron, BAY86-5046)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be able to join the study. Exclusion Criteria: Pregnancy Patients with a history of hypersensitivity to natural or recombinant interferon-beta, human albumin or to any of the excipients Patients with a history of severe depressive disorders and/or suicidal ideation Patient with decompensated liver disease Patient with epilepsy not adequately controlled by treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Interferon-1beta (Betaseron, BAY86-5046)<br>* Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To collect observational local data about effectivity related to physical disability progression on the daily routine basis in patients treated with Betaferon |  | Every 6 months for 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate Betaferon safety on the daily routine basis |  | Every 6 months | 
| To evaluate patient adherence to Betaferon treatment |  | Every 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MS, Multiple Sclerosis, Betaferon, Colombia